CA2291709A1 - Nouveaux inhibiteurs d'angiogenese - Google Patents

Nouveaux inhibiteurs d'angiogenese Download PDF

Info

Publication number
CA2291709A1
CA2291709A1 CA002291709A CA2291709A CA2291709A1 CA 2291709 A1 CA2291709 A1 CA 2291709A1 CA 002291709 A CA002291709 A CA 002291709A CA 2291709 A CA2291709 A CA 2291709A CA 2291709 A1 CA2291709 A1 CA 2291709A1
Authority
CA
Canada
Prior art keywords
pyrazolo
pyrimidine
pyridyl
compound
comprised
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002291709A
Other languages
English (en)
Inventor
Mark T. Bilodeau
Randall W. Hungate
Richard L. Kendall
Ruth Rutledge
Kenneth A. Thomas, Jr.
Robert Rubino
Mark E. Fraley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800681.0A external-priority patent/GB9800681D0/en
Application filed by Individual filed Critical Individual
Publication of CA2291709A1 publication Critical patent/CA2291709A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

La présente invention concerne des composés qui inhibent des enzymes de type tyrosine kinase, des compositions qui contiennent ces composés inhibant la tyrosine kinase, et des procédés d'utilisation des inhibiteurs de tyrosine kinase permettant de traiter des états/maladies dépendant de la tyrosine kinase tels que l'angiogénèse, le cancer, l'athérosclérose, la rétinopathie diabétique ou des maladies auto-immunes chez les mammifères.
CA002291709A 1997-05-30 1998-05-26 Nouveaux inhibiteurs d'angiogenese Abandoned CA2291709A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4807697P 1997-05-30 1997-05-30
US60/048,076 1997-05-30
GB9800681.0 1998-01-14
GBGB9800681.0A GB9800681D0 (en) 1998-01-14 1998-01-14 Novel angiogenesis inhibitors
PCT/US1998/010590 WO1998054093A1 (fr) 1997-05-30 1998-05-26 Nouveaux inhibiteurs d'angiogenese

Publications (1)

Publication Number Publication Date
CA2291709A1 true CA2291709A1 (fr) 1998-12-03

Family

ID=26312935

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002291709A Abandoned CA2291709A1 (fr) 1997-05-30 1998-05-26 Nouveaux inhibiteurs d'angiogenese

Country Status (5)

Country Link
EP (1) EP0984692A4 (fr)
JP (1) JP2002501532A (fr)
AU (1) AU734009B2 (fr)
CA (1) CA2291709A1 (fr)
WO (1) WO1998054093A1 (fr)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002523498A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
AU760020B2 (en) * 1998-08-31 2003-05-08 Merck & Co., Inc. Novel angiogenesis inhibitors
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6265403B1 (en) * 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
PL205557B1 (pl) 1999-02-10 2010-05-31 Astrazeneca Ab Pochodne indolu
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1188244B1 (fr) * 1999-03-26 2004-11-10 Microsoft Corporation Codage adaptatif sans perte de donnees alphabetiques finies
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
KR100834823B1 (ko) 2000-08-09 2008-06-09 아스트라제네카 아베 신놀린 화합물
WO2002012226A1 (fr) 2000-08-09 2002-02-14 Astrazeneca Ab Derives de la quinoline presentant une activite inhibant le facteur de croissance vegf
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
SI2311825T1 (sl) 2000-12-21 2016-02-29 Novartis Ag Pirimidinamini kot angiogenetski modulatorji
PE20020801A1 (es) 2001-01-05 2002-09-06 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7279473B2 (en) 2001-12-17 2007-10-09 Smithkline Beecham Corporation Pyrazolopyridazine derivatives
KR101093345B1 (ko) 2002-02-01 2011-12-14 아스트라제네카 아베 퀴나졸린 화합물
EP1483268A2 (fr) 2002-03-01 2004-12-08 Pfizer Inc. Derives indolyl-uree de thienopyridines utilises comme agents antiangiogeniques, et leurs methodes d'utilisation
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
JP2005524672A (ja) 2002-03-09 2005-08-18 アストラゼネカ アクチボラグ Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体
ES2287476T3 (es) 2002-05-10 2007-12-16 Smithkline Beecham Corporation Pirazolopirimidinas sustituidas.
US7449488B2 (en) * 2002-06-04 2008-11-11 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CZ20023575A3 (cs) * 2002-10-25 2004-01-14 Léčiva, A.S. Způsob výroby N-ethyl-N-[3-(3-methyl-pyrazolo[1,5-a]pyrimidin-7-yl)-fenyl]-acetamidu (zaleplonu)
RS20050430A (en) 2002-12-19 2007-08-03 Pfizer Inc., 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
BRPI0407827B8 (pt) 2003-02-26 2021-05-25 Sugen Inc compostos de aminoeteroarila como inibidores de proteína cinase e respectivos usos
KR20050115252A (ko) 2003-02-28 2005-12-07 데이진 화-마 가부시키가이샤 피라졸로[1,5-ａ]피리미딘 유도체
EP1608652A1 (fr) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Composes pyrazolopyrimidines et leur utilisation en medecine
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0314262D0 (en) 2003-06-19 2003-07-23 Univ Nottingham Trent Novel compounds and methods of using the same
WO2005021554A1 (fr) 2003-08-29 2005-03-10 Pfizer Inc. Thienopyridine-phenylacetamides et leurs derives utiles comme nouveaux agents anti-angiogeniques
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
DE10356579A1 (de) 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
WO2005063756A1 (fr) * 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc Antagonistes du recepteur de crf et procedes correspondants
OA13349A (en) 2003-12-23 2007-04-13 Pfizer Novel quinoline derivatives.
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
PL1786785T3 (pl) 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
WO2006033795A2 (fr) * 2004-09-17 2006-03-30 Wyeth Methode d'utilisation de pyrazolo [1,5-a] pyrimidines substituees
ZA200704476B (en) * 2004-11-04 2008-09-25 Vertex Pharma Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
EP2444099A1 (fr) 2005-03-31 2012-04-25 Agensys, Inc. Anticorps et molécules correspondantes se liant aux protéines 161P2F10B
KR100990027B1 (ko) 2005-04-26 2010-10-26 화이자 인코포레이티드 Ｐ-카드헤린 항체
RS54393B1 (en) 2005-09-07 2016-04-28 Amgen Fremont Inc. HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR
ES2374450T3 (es) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
UY29826A1 (es) 2005-09-30 2007-04-30 Astrazeneca Ab Derivados de pirimidina, sales farmaceuticamente aceptables, esteres de los mismos hidrolisables in vivo, procesos de preparacion y aplicaciones
EP1931676B1 (fr) 2005-10-06 2011-11-16 Schering Corporation Pyrazolopyrimidines en tant qu'inhibiteurs de protéines kinases
JP4383525B2 (ja) 2006-05-09 2009-12-16 ファイザー・プロダクツ・インク シクロアルキルアミノ酸誘導体およびその医薬組成物
EP1900739A1 (fr) * 2006-08-30 2008-03-19 Cellzome Ag Dérivés de diazolodiazine comme inhibiteurs de kinases
US20100093760A1 (en) * 2006-09-12 2010-04-15 The General Hospital Corporation Methods for identifying compounds that modulate cell signaling and methods employing such compounds
MY146474A (en) * 2006-11-06 2012-08-15 Supergen Inc Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
JP5442448B2 (ja) * 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド Ｆｇｆｒインヒビターとしての二環式ヘテロ環式化合物
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
CA2672213C (fr) 2006-12-22 2016-02-16 Astex Therapeutics Limited Derives d'amine bicyclique en tant qu'inhibiteurs de tyrosine kinase
EP2178375B1 (fr) 2007-07-20 2014-09-24 Merck Sharp & Dohme Corp. Dérivés de la pyrazoloý1,5-a¨pyrimidine
EP2185574B1 (fr) 2007-09-07 2013-05-08 Agensys, Inc. Anticorps et molécules apparentées qui se lient aux protéines 24p4c12
JP5372763B2 (ja) * 2007-09-28 2013-12-18 協和発酵キリン株式会社 皮膚疾患の予防及び／または治療剤
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
JP5643105B2 (ja) * 2007-12-14 2014-12-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規イミダゾ［１，２−ａ］ピリジン及びイミダゾ［１，２−ｂ］ピリダジン誘導体
NZ586662A (en) 2007-12-19 2012-08-31 Vertex Pharma PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JANUS KINASE 2 INHIBITORS
EP2265603B1 (fr) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibiteurs de la voie de signalisation bmp
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
JP5836125B2 (ja) 2008-10-16 2015-12-24 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
EP2393814A1 (fr) 2009-02-09 2011-12-14 SuperGen, Inc. Inhibiteurs pyrrolopyrimidinyle de l'axi kinase
EP2400985A2 (fr) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Thérapie anti-cancer combinée
JP2012519170A (ja) 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 生体内の腫瘍細胞のｅｍｔステータスをモニターするためのｉｎｓｉｔｕ法
WO2010099138A2 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Procédés pour l'identification d'agents qui inhibent les cellules tumorales de type mésenchymateuses ou leur formation
EP2401613A2 (fr) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
WO2010099363A1 (fr) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Méthodes d'identification d'agents qui inhibent les cellules cancéreuses mésenchymateuses ou leur formation
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
CN102482715A (zh) 2009-07-13 2012-05-30 霍夫曼-拉罗奇有限公司 用于癌症治疗的诊断方法和组合物
WO2011014726A1 (fr) 2009-07-31 2011-02-03 Osi Pharmaceuticals, Inc. Polythérapie par inhibiteur de mtor et inhibiteur de l’angiogenèse
JP2013503846A (ja) 2009-09-01 2013-02-04 ファイザー・インク ベンズイミダゾール誘導体
KR20120105423A (ko) 2009-09-11 2012-09-25 제넨테크, 인크. 항암제에 반응할 증가된 가능성을 갖는 환자를 확인하는 방법
BR112012005670A2 (pt) 2009-09-17 2017-01-10 Hoffmann La Roche ''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso
WO2011073521A1 (fr) 2009-12-15 2011-06-23 Petri Salven Méthodes pour l'enrichissement de cellules progénitrices endothéliales adultes et leurs utilisations
MX343383B (es) 2010-02-12 2016-11-03 Pfizer Inc * Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona.
WO2011109584A2 (fr) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de kinase du récepteur du facteur de croissance insulinique 1
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US8815874B2 (en) 2010-03-05 2014-08-26 Kyowa Hakko Kirin Co., Ltd. Pyrazolopyrimidine derivative
WO2011153224A2 (fr) 2010-06-02 2011-12-08 Genentech, Inc. Procédés diagnostiques et compositions de traitement du cancer
EP2582727B8 (fr) 2010-06-16 2017-04-19 University of Pittsburgh- Of the Commonwealth System of Higher Education Anticorps dirigés contre l'endoplasmine et leur utilisation
BR112013001429A2 (pt) 2010-07-19 2016-05-31 Hoffmann La Roche método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer
CA2804246A1 (fr) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Methode d'identification d'un patient presentant une probabilite accrue de repondre a un traitement anticancereux
SG187592A1 (en) 2010-07-23 2013-03-28 Univ Boston Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
BR112013008695A2 (pt) 2010-09-27 2016-06-21 Proximagen Ltd compostos de 7-hidróxi-pirazol[1,5-a] pirimidina e seu uso como antagonistas do receptor ccr2
WO2012042421A1 (fr) 2010-09-29 2012-04-05 Pfizer Inc. Procédé de traitement de la croissance cellulaire anormale
US9056865B2 (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2-derivatives as smoothened receptor modulators
WO2012116040A1 (fr) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Marqueurs biologiques prédictifs d'une réponse anticancéreuse aux inhibiteurs de la kinase du récepteur du facteur de croissance 1 analogue à l'insuline dans le carcinome hépatocellulaire
US8748435B2 (en) 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US20140178368A1 (en) 2011-04-19 2014-06-26 Leslie Lynne SHARP Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
WO2012149014A1 (fr) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
CN104023729A (zh) 2011-09-02 2014-09-03 协和发酵麒麟株式会社 趋化因子受体活性调节剂
JP5914667B2 (ja) 2011-09-22 2016-05-11 ファイザー・インク ピロロピリミジンおよびプリン誘導体
ES2654160T3 (es) 2011-10-04 2018-02-12 Igem Therapeutics Limited Anticuerpos de IgE anti-HMW-MAA
RU2014114015A (ru) 2011-11-08 2015-12-20 Пфайзер Инк. Способы лечения воспалительных расстройств с использованием антител против m-csf
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
ES2644758T3 (es) 2012-10-16 2017-11-30 Tolero Pharmaceuticals, Inc. Moduladores de PKM2 y métodos para su uso
SI3808749T1 (sl) 2012-12-07 2023-07-31 Vertex Pharmaceuticals Incorporated Pirazolo(1,5-A)pirimidini za uporabo kot zaviralci ATR kinaze pri zdravljenju rakavih bolezni
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
ES2738493T3 (es) 2013-03-14 2020-01-23 Tolero Pharmaceuticals Inc Inhibidores de JAK2 y ALK2 y métodos para su uso
EP2970311A4 (fr) 2013-03-14 2016-11-23 Brigham & Womens Hospital Inhibiteurs de bmp et leurs procédés d'utilisation
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
EP2970288A1 (fr) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de la kinase atr
WO2014143241A1 (fr) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de la kinase atr
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
WO2015051302A1 (fr) 2013-10-04 2015-04-09 Aptose Biosciences Inc. Compositions et procédés de traitement de cancers
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
RU2687276C2 (ru) 2013-12-06 2019-05-13 Вертекс Фармасьютикалз Инкорпорейтед Соединения, пригодные для использования в качестве ингибиторов atr киназы
WO2015149721A1 (fr) 2014-04-04 2015-10-08 Crown Bioscience, Inc.(Taicang) Méthodes permettant de déterminer la sensibilité à des inhibiteurs de mek/erk
WO2015155624A1 (fr) 2014-04-10 2015-10-15 Pfizer Inc. Dérivés de dihydropyrrolopyrimidine
JP6574203B2 (ja) 2014-04-30 2019-09-11 ファイザー・インク シクロアルキル結合ジヘテロ環誘導体
NZ764151A (en) 2014-06-05 2023-12-22 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
CA2950780C (fr) 2014-06-17 2023-05-16 Vertex Pharmaceuticals Incorporated Methode de traitement anticancereux utilisant une association d'inhibiteurs de chk1 et d'atr
WO2016001789A1 (fr) 2014-06-30 2016-01-07 Pfizer Inc. Dérivés de pyrimidine en tant qu'inhibiteurs de pi3k destinés à être utilisés dans le traitement du cancer
WO2016011019A1 (fr) 2014-07-15 2016-01-21 The Brigham And Women's Hospital, Inc. Compositions et procédés d'inhibition de la bmp
US10934360B2 (en) 2014-07-31 2021-03-02 The Hong Kong University Of Science And Technology Human monoclonal antibodies against EPHA4 and their use
EP3233829B1 (fr) 2014-12-18 2019-08-14 Pfizer Inc Dérivés de pyrimidine et de triazine, et leur utilisation comme inhibiteurs d'axl
WO2016172214A1 (fr) 2015-04-20 2016-10-27 Tolero Pharmaceuticals, Inc. Prédiction de la réaction à l'alvocidib par identification de profil mitochondrial
EP3288957A4 (fr) 2015-05-01 2019-01-23 Cocrystal Pharma, Inc. Analogues de nucléosides à utiliser pour le traitement d'infections par des virus de la famille des flaviviridae et du cancer
KR102608921B1 (ko) 2015-05-18 2023-12-01 스미토모 파마 온콜로지, 인크. 생체 이용률이 증가된 알보시딥 프로드러그
WO2017009751A1 (fr) 2015-07-15 2017-01-19 Pfizer Inc. Dérivés de pyrimidine
KR20180034538A (ko) 2015-08-03 2018-04-04 톨레로 파마수티컬스, 인크. 암의 치료를 위한 병행 요법
EP3355926A4 (fr) 2015-09-30 2019-08-21 Vertex Pharmaceuticals Inc. Méthode de traitement du cancer utilisant une association d'agents endommageant l'adn et d'inhibiteurs de l'atr
EA201891304A1 (ru) 2015-12-03 2019-01-31 Агиос Фармасьютикалс, Инк. ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
CN106632260B (zh) * 2016-09-29 2019-04-26 上海天慈生物谷生物工程有限公司 一种小分子激酶抑制剂的制备方法
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
US10132797B2 (en) 2016-12-19 2018-11-20 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
US11497756B2 (en) 2017-09-12 2022-11-15 Sumitomo Pharma Oncology, Inc. Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
WO2019075367A1 (fr) 2017-10-13 2019-04-18 Tolero Pharmaceuticals, Inc. Activateurs de pkm2 en combinaison avec des espèces réactives de l'oxygène pour le traitement du cancer
CA3103995A1 (fr) 2018-07-26 2020-01-30 Sumitomo Dainippon Pharma Oncology, Inc. Procedes de traitement de maladies associees a l'expression anormale d'acvr1 et inhibiteurs d'acvr1 destines a etre utilises dans ceux-ci
EP3890749A4 (fr) 2018-12-04 2022-08-03 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de cdk9 et leurs polymorphes destinés à être utilisés en tant qu'agents pour le traitement du cancer
WO2020167990A1 (fr) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprenant des inhibiteurs de protéine kinase hétérocycliques
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
EP3941463A1 (fr) 2019-03-22 2022-01-26 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprenant des modulateurs de pkm2 et méthodes de traitement les utilisant
JP7343622B2 (ja) * 2019-06-14 2023-09-12 シージーンテック （スーチョウ， チャイナ） カンパニー リミテッド Ｆｇｆｒとｖｅｇｆｒ二重阻害剤としての縮合環系化合物
WO2021155006A1 (fr) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibiteurs de kinases dépendantes des cyclines et leurs utilisations
GR1010096B (el) * 2020-07-02 2021-10-08 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε, Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2206080A1 (fr) * 1995-09-28 1997-04-03 Otsuka Pharmaceutical Factory, Inc. Analgesiques
WO1997029109A1 (fr) * 1996-02-07 1997-08-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidines en tant qu'antagonistes du recepteur de crf

Also Published As

Publication number Publication date
WO1998054093A1 (fr) 1998-12-03
AU734009B2 (en) 2001-05-31
AU7594498A (en) 1998-12-30
EP0984692A1 (fr) 2000-03-15
EP0984692A4 (fr) 2001-02-21
JP2002501532A (ja) 2002-01-15

Similar Documents

Publication Publication Date Title
US6235741B1 (en) Angiogenesis inhibitors
CA2291709A1 (fr) Nouveaux inhibiteurs d'angiogenese
AU744939B2 (en) Novel angiogenesis inhibitors
AU760020B2 (en) Novel angiogenesis inhibitors
US6465484B1 (en) Angiogenesis inhibitors
US6162804A (en) Tyrosine kinase inhibitors
AU747427B2 (en) Novel angiogenesis inhibitors
US6265403B1 (en) Angiogenesis inhibitors
US6380203B1 (en) Angiogenesis inhibitors
MX2008012860A (es) Desazapurinas de utilidad como inhibidores de janus cinasas.
JP2009536617A (ja) タンパク質キナーゼの阻害剤として有用なチアゾール、イミダゾール、およびピラゾール
KR20110039278A (ko) 단백질 키나제 억제제
WO2005000813A1 (fr) Derives d'heteroarylamino-phenylcetone et leur utilisation en tant qu'inhibiteurs de kinases
JP2010510216A (ja) プロテインキナーゼのインヒビターとして有用な化合物
JP2002544272A (ja) 置換３−ピリジル−４−アリールピロール並びに関連した治療及び予防法
US6228871B1 (en) Angiogenesis inhibitors
US6720332B2 (en) Oxindole derivatives
AU2002334837B2 (en) Triazepine derivatives as neurotrophic agents
KR20240028959A (ko) 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
CN114746408A (zh) 炔基-(杂芳基)-甲酰胺hcn1抑制剂
AU2008278824A1 (en) Compounds for treating Duchenne muscular dystrophy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead